Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) were down 2.8% on Thursday . The company traded as low as $39.49 and last traded at $39.52, with a volume of 216,727 shares. The stock had previously closed at $40.65.

A number of analysts recently weighed in on ITCI shares. Leerink Swann restated a “buy” rating on shares of Intra-Cellular Therapies in a report on Thursday, June 30th. Cowen and Company restated a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, June 29th. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $42.00 price target for the company in a research report on Wednesday, June 29th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $57.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, June 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $70.78.

The company’s 50 day moving average is $40.82 and its 200 day moving average is $35.26. The stock’s market capitalization is $1.75 billion.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.08. During the same period in the prior year, the business earned ($0.61) earnings per share. The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.02 million. The company’s revenue for the quarter was up 283.3% on a year-over-year basis. Analysts forecast that Intra-Cellular Therapies Inc. will post ($3.17) earnings per share for the current year.

A hedge fund recently raised its stake in Intra-Cellular Therapies stock. Marshall Wace LLP increased its position in Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 23.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,148 shares of the biopharmaceutical company’s stock after buying an additional 4,410 shares during the period. Marshall Wace LLP owned about 0.05% of Intra-Cellular Therapies worth $1,245,000 at the end of the most recent reporting period.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).